Database→Sermorelin

Tier 2HormonalCognitiveAnti-agingPREMIUM

Sermorelin

Sermorelin Acetate (GHRH 1-29) · Geref (discontinued) · Growth Hormone-Releasing Hormone Fragment

Formerly FDA-approved (diagnostic 1990; pediatric GHD therapeutic 1997). Voluntarily discontinued by manufacturer 2008 for commercial reasons -- NOT for safety or efficacy. FDA confirmed 2013: withdrawal was not due to safety or effectiveness concerns. Currently: not on FDA Category 2 compounding prohibition list. Available via compounding pharmacies for off-label use.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

Sermorelin (GHRH 1-29) is the only compound in this research series with a history of full FDA approval, voluntarily discontinued for commercial reasons in 2008. It stimulates endogenous GH release via pituitary GHRH receptors with a built-in somatostatin safety ceiling. Human evidence includes the approved pediatric GHD indication, small but consistent adult aging body composition data, and replicated cognitive function improvements in aging and MCI from the University of Washington research program.

🔒

Full Profile: Premium Members Only

The complete Sermorelin profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use